Form 4: Cambrian BioPharma Sells SNSE Shares

Cambrian BioPharma Inc., a 10% owner and director of Sensei Biotherapeutics, Inc., reported multiple sales of common stock totaling 21,295 shares in early December 2025.

Summary

• Cambrian BioPharma Inc., a 10% owner and director of Sensei Biotherapeutics, Inc. (SNSE), reported sales of common stock.
• Transactions occurred on December 4 and December 5, 2025.
• A total of 21,295 shares were sold across four separate transactions.
• The sales were executed pursuant to a Rule 10b5-1(c) plan, indicating they were pre-scheduled.
• Weighted average sale prices ranged from $9.06 to $13.16 per share.
• Following these transactions, Cambrian BioPharma Inc. beneficially owns 161,359 shares of Sensei Biotherapeutics common stock.
• The reported share amounts reflect an adjustment for a 1-for-20 stock split effectuated by Sensei Biotherapeutics.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a significant shareholder reducing their stake, which can sometimes be perceived negatively by the market. However, the execution under a 10b5-1 plan mitigates some of the negative implications, suggesting a planned portfolio adjustment rather than a reaction to adverse news.

Negatives

• A significant shareholder and director, Cambrian BioPharma Inc., reduced its stake in Sensei Biotherapeutics by selling 21,295 shares.
• The sales occurred over two days, indicating a systematic reduction in holdings.

Future Outlook

NA

Management Comments

• James Peyer, CEO of Cambrian BioPharma Inc., may direct the voting and disposition of shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors.
• Mr. Peyer disclaims beneficial ownership of the shares held by Cambrian BioPharma Inc.

Industry Context

This Form 4 filing reports an insider sale by a significant shareholder in a biopharmaceutical company. Such sales are common for institutional investors managing their portfolios, especially when executed under a Rule 10b5-1 plan, which allows for pre-scheduled transactions to avoid accusations of trading on material non-public information. The biopharma industry often sees volatility, and institutional investors may adjust holdings based on various factors including portfolio rebalancing, investment strategy changes, or company-specific developments.

Stakeholder Impact

• Shareholders: The sale by a 10% owner and director could be interpreted as a lack of confidence or a portfolio rebalancing, potentially putting downward pressure on the stock price. However, the 10b5-1 plan suggests a pre-planned action.

Key Dates

Recommendation

While the sale by a significant insider could be a negative signal, the execution under a Rule 10b5-1 plan suggests a pre-planned portfolio adjustment rather than a reaction to new adverse information. Without additional context on Sensei Biotherapeutics' operational performance or strategic outlook, a 'hold' recommendation is appropriate, advising investors to monitor future developments and the company's fundamentals rather than reacting solely to this insider transaction.

Keywords

Sensei Biotherapeutics, SNSE, Cambrian BioPharma, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Biopharma, Equity Sales, Director Sales, 10% Owner